Review Article
Efficacy of Xuebijing Injection for Acute Pancreatitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Table 2
Characteristics of included patients.
| | First author (year) | No. pts | Etiology of acute pancreatitis | Sex (male/female) (n) | Age (mean) | Groups | Follow-up (days) | Overall response (n) | Complete response (n) | No response (n) |
| | Li (2020) | 32 | NA | 16/16 | 43.1 | XBJ group | 14 | 28 | 15 | 4 | | 32 | NA | 17/15 | 43.6 | Control group | 14 | 20 | 8 | 12 | | Zhan (2019) | 39 | Biliary diseases 14; alcohol 11; surgery 4; overeating 10 | 28/11 | 46.6 | XBJ group | 10 | 39 | 32 | 0 | | 39 | Biliary diseases 15; alcohol 11; surgery 5; overeating 7; other 1 | 24/15 | 45.9 | Control group | 10 | 37 | 23 | 2 | | Yuan (2019) | 35 | Biliary diseases 13; alcohol 15; hyperlipidemia 7 | 19/16 | 50.7 | XBJ group | 7 | 34 | 28 | 1 | | 35 | Biliary diseases 13; alcohol 13; hyperlipidemia 9 | 21/14 | 49.8 | Control group | 7 | 28 | 15 | 7 | | Hu (2019) | 67 | NA | 40/27 | 41.5 | XBJ group | 10 | 64 | 53 | 3 | | 67 | NA | 39/28 | 41.4 | Control group | 10 | 56 | 41 | 11 | | Zhang (2018) | 35 | NA | 19/16 | 42.8 | XBJ group | 7 | 33 | 29 | 2 | | 35 | NA | 20/15 | 43.1 | Control group | 7 | 27 | 22 | 8 | | Zhang (a) (2018) | 37 | NA | 18/19 | 39.3 | XBJ group | 7 | 31 | 20 | 6 | | 37 | NA | 17/20 | 38.0 | Control group | 7 | 23 | 13 | 14 | | Zhang (b) (2018) | 40 | Biliary diseases 14; alcohol 11; surgery 4; overeating 10 | 23/17 | 42.1 | XBJ group | 7 | 39 | 34 | 1 | | 40 | Biliary diseases 20; alcohol 10; overeating 9; other 1 | 25/15 | 40.5 | Control group | 7 | 32 | 25 | 8 | | Fan (2018) | 20 | NA | 11/9 | 38.6 | XBJ group | 7 | 17 | 9 | 3 | | 20 | NA | 12/8 | 38.9 | Control group | 7 | 12 | 6 | 8 | | Zha (2018) | 49 | NA | NA | NA | XBJ group | 7 | 46 | 28 | 3 | | 49 | NA | NA | NA | Control group | 7 | 39 | 18 | 10 | | Ji (2017) | 61 | NA | 48/13 | 48.0 | XBJ group | 7 | 59 | 50 | 2 | | 61 | NA | 46/15 | 48.2 | Control group | 7 | 51 | 39 | 10 | | Chen (2017) | 43 | NA | 24/19 | 43.1 | XBJ group | 7 | 40 | 29 | 3 | | 43 | NA | 25/18 | 43.3 | Control group | 7 | 33 | 21 | 10 | | Liu (2017) | 52 | NA | 29/23 | 42.5 | XBJ group | 7 | 49 | 35 | 3 | | 42 | NA | 24/18 | 40.5 | Control group | 7 | 31 | 19 | 11 | | Gao (2016) | 44 | NA | 23/21 | 41.9 | XBJ group | 7 | 41 | 31 | 3 | | 44 | NA | 24/20 | 42.6 | Control group | 7 | 32 | 21 | 12 | | Chen (2015) | 73 | Biliary diseases 43; alcohol or overeating 30 | 45/28 | 42.7 | XBJ group | 7 | 72 | 51 | 1 | | 73 | Biliary diseases 42; alcohol or overeating 31 | 46/27 | 42.8 | Control group | 7 | 65 | 34 | 8 | | Chen (2015) | 52 | Biliary diseases 25; alcohol 109; overeating 8; hyperlipidemia 6; other 3 | 30/22 | 53.6 | XBJ group | 7 | 48 | 43 | 4 | | 52 | Biliary diseases 24; alcohol 9; overeating 9; hyperlipidemia 8; other 2 | 31/21 | 53.7 | Control group | 7 | 38 | 31 | 14 | | Zhang (2015) | 21 | NA | NA | NA | XBJ group | NA | 19 | 14 | 2 | | 18 | NA | NA | NA | Control group | NA | 15 | 9 | 3 | | Zhu (2015) | 25 | NA | 17/8 | 36.5 | XBJ group | NA | 23 | 15 | 2 | | 25 | NA | 18/7 | 36.7 | Control group | NA | 18 | 7 | 7 | | Liu (2015) | 40 | NA | 28/12 | 32.6 | XBJ group | 7 | 38 | 30 | 2 | | 40 | NA | 26/14 | 30.4 | Control group | 7 | 34 | 22 | 6 | | Bai (2015) | 50 | NA | 33/17 | 46.7 | XBJ group | 7 | 48 | 29 | 2 | | 48 | NA | 30/18 | 49.0 | Control group | 7 | 37 | 20 | 11 | | Yang (2014) | 31 | NA | 22/9 | 40.3 | XBJ group | 5–7 | 29 | 26 | 2 | | 31 | NA | 20/11 | 41.2 | Control group | 5–7 | 23 | 18 | 8 | | Liu (2014) | 25 | Biliary diseases 2; alcohol 12; overeating 9; other 2 | 16/9 | 48.2 | XBJ group | 7 | 23 | 16 | 2 | | 20 | Biliary diseases 4; alcohol 9; overeating 5; other 2 | 13/7 | 49.1 | Control group | 7 | 14 | 10 | 6 | | Lin (2012) | 43 | NA | 26/17 | 38.8 | XBJ group | 7 | 41 | 24 | 2 | | 43 | NA | 28/15 | 39.2 | Control group | 7 | 34 | 18 | 9 | | Hong (2012) | 62 | NA | 40/22 | 44.5 | XBJ group | 7 | 60 | 50 | 2 | | 62 | NA | 40/22 | 44.9 | Control group | 7 | 56 | 37 | 6 |
|
|
Abbreviations: Pts: patients; XBJ: Xuebijing injection.
|
